Rheumatology & Autoimmune

Arthritis, lupus, vasculitis, biologics, and immune‑modulating therapies.

  • 3 Tracked terms
  • Last 30 days Feed window
Search within this topic Ask AI about this topic All topics

What this topic collects on

An article joins this feed when it matches these terms. Each one is also a search of its own.

Latest in Rheumatology & Autoimmune


koreabiomed.com > news > articleViewAmp.html

[Interview] Pediatric Crohn???s disease needs broader treatment options, specialist says

17+ hour, 31+ min ago   (1628+ words) Treatment goals for Crohn’s disease are shifting from simply controlling symptoms such as abdominal pain and diarrhea to suppressing intestinal inflammation as much as possible and achieving deeper remission, including endoscopic remission, or “mucosal healing.” The stakes are particularly high…...


biotechdispatch.com.au > news > noxopharm-moves-lupus-skin-therapy-toward-next-human-trial

Noxopharm moves lupus skin therapy toward next human trial

17+ hour, 4+ min ago   (292+ words) Noxopharm has announced that its lead experimental therapy, SOF-SKN, will advance to an extension clinical study in patients with cutaneous lupus erythematosus, a painful and disfiguring skin condition for which no targeted treatment currently exists. The Sydney-based company said the…...


cuh.nhs.uk > news > study-early-treatment-prevent-long-term-complications-crohns

Study shows early treatment can prevent long-term complications in Crohn’s disease

2+ day, 2+ hour ago   (1121+ words) MyChart - our app for patients Find out more about taking part in research A healthier life for everyone through care, learning and research. Our strategy for 2026-2031 sets out the next phase for CUH. Join our exceptional team Take a look…...


bioengineer.org > hidden-protein-bosses-the-cleanup-crew-that-keeps-lupus-at-bay

Hidden Protein Bosses the Cleanup Crew That Keeps Lupus at Bay

1+ day, 18+ hour ago   (76+ words) Every second of every day, billions of your cells quietly die. Far from being a catastrophe, this mass dying is part of the body’s routine housekeeping, and a specialized force of immune cells stands ready to devour the wreckage. Macrophages,…...


bioengineer.org > common-lupus-gene-variant-boosts-antiviral-defenses-at-the-cost-of-autoimmunity-risk

Common Lupus Gene Variant Boosts Antiviral Defenses at the Cost of

1+ day, 18+ hour ago   (778+ words) Why do genetic variants that raise the risk of autoimmune disease remain so common in the human population? Evolutionary logic would seem to argue that harmful versions of genes should slowly disappear, yet many of the inherited risk factors for…...


docwirenews.com > videos > the-importance-of-adequate-treatment-for-older-adults-with-inflammatory-bowel-disease

Balancing Disease Control and Safety for Older Adults With IBD

3+ day, 21+ hour ago   (146+ words) Adam Faye, MD, of NYU Langone Health, New York, New York, shares results from a study evaluating the safety of guselkumab among older populations of patients with immune-mediated inflammatory diseases, such as inflammatory bowel disease (IBD), psoriasis, and psoriatic arthritis....


tradingview.com > news > urn:summary_document_transcript:quartr.com:4145913:0-ifrx-inf904-advances-in-anca-vasculitis-with-phase-ii-trials-planned-and-strong-regulatory-engagement

IFRX: INF904 advances in ANCA vasculitis with phase II trials planned and strong regulatory engagement

5+ day, 47+ min ago   (78+ words) TradingView IFRX: INF904 advances in ANCA vasculitis with phase II trials planned and strong regulatory engagement A strategic pivot prioritizes ANCA vasculitis with INF904, designed for better safety and efficacy, and vilobelimab as a bridging option amid competitor withdrawals. Regulatory engagement is…...


firstwordpharma.com > story > 7967798

Beeline buzzes ahead to pivotal lupus trials after mid-stage success

5+ day, 4+ hour ago   (12+ words) FirstWord Pharma...


drugtargetreview.com > experimental-rna-drug-reverses-scleroderma-signs-in-preclinical-study > 2136427.article

TY1 RNA drug reverses systemic sclerosis signs in preclinical study

5+ day, 7+ hour ago   (590+ words) Scientists at Cedars-Sinai have demonstrated that TY1, a synthetic non-coding RNA originally developed to address heart attack-related tissue damage, can reduce inflammation, DNA damage and organ scarring in preclinical models of systemic sclerosis. Researchers at Cedars-Sinai Health Sciences University have used…...


emjreviews.com > rheumatology > news > hepatitis-c-in-cryoglobulinemic-vasculitis-autoimmune-outcomes

Hepatitis C in Cryoglobulinemic Vasculitis: Autoimmune Outcomes

5+ day, 9+ hour ago   (440+ words) EMJ This site is intended for healthcare professionals Hepatitis C in Cryoglobulinemic Vasculitis: Autoimmune Outcomes - Hepatitis C-related cryoglobulinemic vasculitis confers better event-free survival than autoimmune causes. - Low C4 complement and rheumatoid factor positivity independently predict poor event-free survival. - Underlying autoimmune etiology,…...